Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
Dr. Girgenti, a global leader in clinical research and drug development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller. With the addition of Dr. Girgenti, Melinta expects to expand its world-class portfolio while continuing to drive operational excellence.
“At Melinta, we’re on a legendary journey to become the leader in acute care and continue to serve patients with critical, unmet needs. I’m excited to welcome Doug to the team as a seasoned leader with extensive medical, scientific and operational experience,” Ms. Miller said. “I’m confident he’ll play a key role as we evaluate potential assets to expand our portfolio and help lead our team to meet clinical, operational, regulatory and financial objectives.”
Dr. Girgenti joins Melinta from Magenta Therapeutics where he led clinical development programs for stem-cell mobilization and autoimmune diseases. Prior to Magenta, Dr. Girgenti led global clinical programs for Wyeth, Pfizer and Boehringer-Ingelheim developing investigational vaccines targeting Staphylococcus aureus and invasive pneumococcal disease as well as numerous small and large molecules in the fields of immunology, stem-cell transplantation, nephrology, ophthalmology, cardiology and rare diseases.
Prior to joining the pharma industry, he was a practicing pediatrician and internist for 10 years, and he served as a medical director and managing physician of multiple medical and surgical subspecialists.
“I’m excited to join this team that is so passionately committed to patients in need,” Dr. Girgenti said. “I look forward to helping lead the way for more sustainable growth through clinical and developmental success while keeping patients at the center of our legendary future.”
About Melinta Therapeutics
Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information.
Source: Melinta Therapeutics, LLC